

MEDICAMEN Biotech Limited



Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2024-25

Date: 14.08.2024

To

**BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001**

**National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051**

BSE Code-531146

NSE Code: MEDICAMEQ

Sub. : Copy of Publication for Un-Audited Financial Results for the quarter ended on June 30, 2024

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 (“the Regulations”), please find enclosed newspaper cutting with regard to the publication of extract of Un-Audited Financial Results of the Company for the quarter ended on June 30, 2024 approved by the Board of Directors at their Meeting held on 13.08.2024.

The copy of the results published in the Financial Express and Jansatta dated August 14, 2024 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,
For Medicamen Biotech Limited

**Parul Choudhary
Company Secretary
ACS-44157**

Encl: As above.



MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower 43, Nehru Place, New Delhi-110019
CIN : L74899DL 1993PLC056594 E-mail : cs@medicamen.com, www.medicamen.com

Un-audited standalone and consolidated financial results for the quarter ended as on 30th June 2024

Rupees in Lacs (Except per Share data)

Sl. No.	Particulars	Standalone				Consolidated			
		Three months period ended		Year ended		Three months period ended		Year ended	
		Un-audited 30.06.2024	Audited 31.03.2024	Un-audited 30.06.2023	Audited 31.03.2024	Un-audited 30.06.2024	Audited 31.03.2024	Un-audited 30.06.2023	Audited 31.03.2024
1	Total income from operations (net)	4205.69	4555.04	4088.26	17468.88	4363.49	4788.57	4232.23	18163.19
2	Net Profit/ (Loss) for the period (before tax, exceptional and/ or Extraordinary items)	301.51	372.51	515.33	1688.79	155.63	265.56	466.33	1307.56
3	Net Profit/ (Loss) for the period before tax (after exceptional and/ or Extraordinary items)	301.51	372.51	515.33	1688.79	155.63	265.56	468.33	1307.56
4	Net Profit/ (Loss) for the period after tax (after exceptional and/ or Extraordinary items)	225.70	310.31	441.70	1329.80	79.87	204.04	394.70	949.40
5	Total comprehensive income for the period (Comprising Profit/ (loss) for the period (after tax) and other Comprehensive income (after tax))	225.70	310.31	441.70	1329.80	79.87	204.04	394.70	949.40
6	Equity Share Capital	1271.46	1271.46	1265.11	1271.46	1271.46	1271.46	1265.11	1271.46
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)								
8	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operation)								
	Basic:	1.78	2.45	3.49	10.50	0.63	1.61	3.12	7.50
	Diluted:	1.78	2.45	3.49	10.50	0.63	1.61	3.12	7.50

Notes:

- The Un-audited financial results for the quarter ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13 August 2024
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - Earning per Share
- Limited review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

For Medicamen Biotech Limited

Sd/-

Rahul Bishnoi
Chairman

Place : New Delhi

Date : 13.08.2024